ART is key to clearing oncogenic HPV genotypes (HR-HPV) in anal mucosa of HIV-positive MSM
Autoři:
Carmen Hidalgo-Tenorio aff001; Concepción Gil-Anguita aff001; Miguel Angel López Ruz aff001; Mohamed Omar aff002; Javier López-Hidalgo aff003; Juan Pasquau aff001
Působiště autorů:
Department of Infectious Diseases; “Virgen de las Nieves” University Hospital, Granada, Spain
aff001; Unit of Infectious Diseases, Jaen “Hospital Complex”, Spain
aff002; Pathology Department; “Virgen de las Nieves” University Hospital, Granada, Spain
aff003
Vyšlo v časopise:
PLoS ONE 14(10)
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pone.0224183
Souhrn
Background
Anal squamous cell carcinoma (ASCC) is one of the most frequent non-AIDS-defining neoplasias in HIV patients, mainly in MSM, and it has been associated with chronic infection with high-risk human papilloma virus (HR-HPV). Our main objective was to determine HR-HPV clearance and acquisition rates and related factors and their relationship with the incidence of HSILs and ASCC in anal mucosa of HIV+ MSM.
Patients and methods
The study included consecutive HIV-infected MSM between May 2010 and December 2018. Data were gathered at baseline and annually on their sexual behavior, CD4 and CD8 levels, plasma HIV viral load, and results of anal cytology, HPV PCR, and high-resolution anoscopy.
Results
Out of the 405 patients studied, 34.9% of patients cleared oncogenic genotypes (IQR: 37–69) within 49 months, and 42.9% acquired new genotypes within 36 months (IQR:12–60). In multivariate analysis, clearance was only significantly influenced by the duration of antiretroviral therapy (ART) (OR: 1.016, 95% CI 1.003–1.030). The incidence of HSILs was 30.86/1,000 patient-years and that of ASCC was 81.22/100,000 patient-years; these incidences were not influenced by the acquisition (acquired: 14.9% vs. non-acquired: 10.4%; p = 0.238) or clearance (cleared 11.4% vs. non-cleared: 13.2%; p = 0.662) rates of these viruses.
Conclusions
The duration of ART appears to positively affect oncogenic genotype clearance in the anal mucosa of HIV+ MSM, although this clearance does not affect the incidence of HSILs or ASCC. The reduction in HSIL+ rate observed in our patients may be attributable to the bundle of measures adopted at our center.
Klíčová slova:
HIV diagnosis and management – Human papillomavirus – Cytology – Human papillomavirus infection – Lesions – Carcinogenesis – Histology – Viruses and cancer
Zdroje
1. Silverberg MJ, Lau B, Justice AC, Engels E, Gill MJ, Goedert JJ, et al Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012; 54: 1026–1034. doi: 10.1093/cid/cir1012 22291097
2. Wexler A, Berson AM, Goldstone SE, Waltzman R, Penzer J, Maisonet OG, et al. Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy. Dis Colon Rectum. 2008; 51: 73–81. doi: 10.1007/s10350-007-9154-7 18066626
3. Raham SV. The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review. Clin Sci (Lond). 2017; 131:2201–2221.
4. Looker KJ, Looker KJ, Rönn MM, Brock PM, Brisson M, Drolet M, et al. Evidence of synergistic relationships between HIV and Human Papillomavirus (HPV): systematic reviews and meta-analyses of longitudinal studies of HPV acquisition and clearance by HIV status, and of HIV acquisition by HPV status. Journal of the international AIDS Society 2018; 21: e2510
5. Yuan T, Fitzpatrick T, Ko NY, Cai Y, Chen Y, Zhao J, et al Circumcision to prevent HIV and other sexually transmitted infections in men who have sex with men: a systematic review and meta-analysis of global data. Lancet Glob Health. 2019; 7: e436–e447. doi: 10.1016/S2214-109X(18)30567-9 30879508
6. Pierce Campbell CM, Lin HY, Fulp W, Papenfuss MR, Salmerón JJ, Quiterio MM et al. Consistent Condom Use Reduces the Genital Human Papillomavirus Burden Among High -Risk Men: The HPV Infection in Men Study. J Infect Dis. 2013; 208: 373–84. doi: 10.1093/infdis/jit191 23644283
7. Hidalgo Tenorio C. Papillomavirus vaccine for women, and for men? Med Clin (Barc). 2019; 152: 264–265.
8. Ramière C, Charre C, Miailhes P, Bailly F, Radenne S, Uhres AC, et al. Patterns of HCV transmission in HIV-infected and HIV-negative men having sex with men. Clin Infect Dis. 2019 Feb 27. pii: ciz160,
9. Kasaie P, Berry SA, Shah MS, Rosenberg ES, Hoover KW, Gift TL, et al. Impact of Providing Preexposure Prophylaxis for Human Immunodeficiency Virus at Clinics for Sexually Transmitted Infections in Baltimore City: An Agent-based Model.Sex Transm Dis. 2018; 45: 791–797 doi: 10.1097/OLQ.0000000000000882 29944642
10. Sewell J, Miltz A, Lampe FC, Cambiano V, Speakman A, Phillips AN, et al. Poly drug use, chemsex drug use, and associations with sexual risk behaviour in HIV-negative men who have sex with men attending sexual health clinics. Int J Drug Policy. 2017; 43: 33–43. doi: 10.1016/j.drugpo.2017.01.001 28189979
11. Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, et al. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. JAMA Intern Med. 2016; 176: 75–84. doi: 10.1001/jamainternmed.2015.4683 26571482
12. Área de Vigilancia de VIH y Comportamientos de Riesgo. Vigilancia Epidemiológica del VIH y sida en España 2017: Sistema de Información sobre Nuevos Diagnósticos de VIH y Registro Nacional de Casos de Sida. Plan Nacional sobre el Sida—D.G. de Salud Pública, Calidad e Innovación / Centro Nacional de Epidemiología—ISCIII. Madrid; Nov 2018.
13. WHO. Global AIDS Update. UNAIDS report. 2016.
14. Stankiewicz Karita HC, Hauge K, Magaret A, Mao C, Schouten J, Grieco V, et al. Effect of Human Papillomavirus Vaccine to Interrupt Recurrence of Vulvar and Anal Neoplasia (VIVA): A Trial Protocol. JAMA Netw Open. 2019; 2: e190819. doi: 10.1001/jamanetworkopen.2019.0819 30977845
15. Cranston RD, Cespedes MS, Paczuski P, Yang M, Coombs RW, Dragavon J, et al. High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Individuals Older Than 26 Years: ACTG 5298. Sex Transm Dis. 2018; 45: 266–271. doi: 10.1097/OLQ.0000000000000745 29528986
16. Hidalgo-Tenorio C, Gil-Anguita C, Ramírez-Taboada J, Esquivias J, López-Ruz MA, Balgahata OM, et al. Risk factors for infection by oncogenic human papillomaviruses in HIV-positive MSM patients in the ART era (2010–2016). Medicine (Baltimore). 2017; 96: e8109.
17. Muñoz N, Bosch FX, de Sanjose S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348:518–527. doi: 10.1056/NEJMoa021641 12571259
18. Solomon D, Davey D, Kurman R, Moriarty A, O´Connor D, Prey M, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA. 2002; 287: 2114–2119. doi: 10.1001/jama.287.16.2114 11966386
19. Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis. 2012; 16: 205–42. doi: 10.1097/LGT.0b013e31825c31dd 22820980
20. Andrés AM, Marzo PF. Chance-corrected measures of reliability and validity in K x K tables. Stat Methods Med Res. 2005; 14: 473–492. doi: 10.1191/0962280205sm412oa 16248349
21. Freeman DH. Applied categorical data analysis. 1987. New York, USA, Marcel Dekker.
22. Nowak RG, Gravitt PE, He X, Ketende S, Dauda W, Omuh H, et al. Prevalence of Anal High-Risk Human Papillomavirus Infections Among HIV-Positive and HIV-Negative Men Who Have Sex With Men in Nigeria. Sex Transm Dis. 2016; 43: 243–8. doi: 10.1097/OLQ.0000000000000431 26967301
23. Cheng SH, Liao KS, Wang CC, Cheng CY, Chu FY. Multiple types of human papillomavirus infection and anal precancerous lesions in HIV-infected men in Taiwan: a cross-sectional study. BMJ Open. 2018; 27: e019894.
24. Arens Y, Gaisa M, Goldstone S, Liu Y, Wisnivesky J, Sigel C, et al. Risk of Invasive Anal Cancer in HIV-Infected Patients with High-Grade Anal Dysplasia: A Population-Based Cohort Study. Dis Colon Rectum. 2019; 62: 934–940. doi: 10.1097/DCR.0000000000001384 30888979
25. Machalek DA, Grulich AE, Hillman RJ, Jin F, Templeton DJ, Tabrizi SN, et al. The Study of the Prevention of Anal Cancer (SPANC): design and methods of a three-year prospective cohort study BMC Public Health. 2013;13: 946 doi: 10.1186/1471-2458-13-946 24107134
26. Tosato Boldrini NA, Bondi Volpini LP, de Freitas LB, Musso C, Merçon de Vargas PR, Spano LC, et al. Anal HPV infection and correlates in HIV-infected patients attending a Sexually Transmitted Infection clinic in Brazil. PLoS One. 2018; 13: e0199058. doi: 10.1371/journal.pone.0199058 29975716
27. Darwich L, Cañadas MP, Videla S, Coll J, Piñol M, Cobarsi P, et al; Condylomata, cytological abnormalities and human papillomavirus infection in the anal canal in HIV-infected men HIV Med. 2012; 13: 549–57 doi: 10.1111/j.1468-1293.2012.01013.x 22435501
28. Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS J Natl Cancer Inst. 2009; 101:1 120–30.
29. Wirtz AL, Zelaya CE, Peryshkina A, McGowan I, Cranston RD, Latkin C, et al. Anal human papillomavirus and HIV: A cross-sectional study among men who have sex with men in Moscow, Russia, 2012–2013. Euro Surveill. 2015; 20: 21095. doi: 10.2807/1560-7917.es2015.20.15.21095 25953132
30. Hidalgo-Tenorio C, de Jesus SE, Esquivias J, Pasquau J. High prevalence and incidence of HPV-related anal cancer precursor lesions in HIV-positive women in the late HAART era. Enferm Infecc Microbiol Clin. 2018; 36: 555–562. doi: 10.1016/j.eimc.2017.10.014 29208455
31. Cranston RD, Carballo-Diéguez A, Gundacker H, Richardson BA, Giguere R, Dolezal C, et al. Prevalence and determinants of anal human papillomavirus infection in men who have sex with men and transgender women. Int J STD AIDS. 2019; 30: 154–162. doi: 10.1177/0956462418797864 30336747
32. Rovelli C, Poli A, Galli L, Cernuschi M, Tamburini AM, Racca S, et al. Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males. PLoS One. 2017; 12: e0186367. doi: 10.1371/journal.pone.0186367 29088236
33. Marra E, Siegenbeek van, Heukelom ML, Leeman A, Waterboer T, Meijer CJLM, et al. Virological and Serological Predictors of Anal High-grade Squamous Intraepithelial Lesions Among Human Immunodeficiency Virus-positive Men Who Have Sex With Men. Clin Infect Dis. 2019; 68:1377–1387. doi: 10.1093/cid/ciy719 30165551
34. Colón-López V, Shiels MS, Machin M, Ortiz AP, Strickler H, Castle PE, et al. Anal Cancer Risk Among People With HIV Infection in the United States. J Clin Oncol. 2018; 36: 68–75. doi: 10.1200/JCO.2017.74.9291 29140774
35. Jin F, Vajdic CM, Law M, Amin J, van Leeuwen M, McGregor S, et al. Incidence and time trends of anal cancer among people living with HIV in Australia. AIDS. 2019; 33: 1361–1368. doi: 10.1097/QAD.0000000000002218 30950880
36. Clarke MA, Wentzensen N. Strategies for screening and early detection of anal cancers: A narrative and systematic review and meta-analysis of cytology, HPV testing, and other biomarkers Cancer Cytopathol. 2018; 126: 447–460. doi: 10.1002/cncy.22018 29797691
37. Nathan M, Singh N. Performance of anal cytology in a clinical setting when measured against histology and high-resolution anoscopy findings. AIDS. 2010; 24: 373–379. doi: 10.1097/QAD.0b013e328333ab8e 20057313
38. Berry JM, Palefsky JM, Jay N, Cheng SC, Darragh TM, Chin-Hong PV. Performance characteristics of anal cytology and human papillomavirus testing in patients with high-resolution anoscopy-guided biopsy of high-grade anal intraepithelial neoplasia. Dis Colon Rectum 2009; 52: 239–247. doi: 10.1007/DCR.0b013e31819793d9 19279418
39. Gudur A, Shanmuganandamurthy D, Szep Z, Poggio JL. An Update on the Current Role of High Resolution Anoscopy in Patients With Anal Dysplasia. Anticancer Res. 2019; 39: 17–23. doi: 10.21873/anticanres.13075 30591436
Článok vyšiel v časopise
PLOS One
2019 Číslo 10
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Nejasný stín na plicích – kazuistika
- Masturbační chování žen v ČR − dotazníková studie
- Těžké menstruační krvácení může značit poruchu krevní srážlivosti. Jaký management vyšetření a léčby je v takovém případě vhodný?
- Fixní kombinace paracetamol/kodein nabízí synergické analgetické účinky
Najčítanejšie v tomto čísle
- Correction: Low dose naltrexone: Effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study
- Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity
- Experimentally validated simulation of coronary stents considering different dogboning ratios and asymmetric stent positioning
- Risk factors associated with IgA vasculitis with nephritis (Henoch–Schönlein purpura nephritis) progressing to unfavorable outcomes: A meta-analysis